Amicus Therapeutics Inc. (NASDAQ:FOLD) traded at $11.55 at close of the session on Tuesday, 11/22/22, made an upward move of 6.45% on its previous day’s price.
Looking at the stock we see that its previous close was $10.85 and the beta (5Y monthly) reads 0.90 with the day’s price range being $10.68 – $11.60. In terms of its 52-week price range, FOLD has a high of $12.96 and a low of $5.91. The company’s stock has gained about 7.84% over that past 30 days.
Amicus Therapeutics Inc. has a market cap of $3.27 billion and is expected to release its quarterly earnings report on Feb 22, 2023 – Feb 27, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$0.19, with the EPS growth for the year raised at -$0.85 for 2022 and -$0.19 for next year. These figures represent 7.60% and 77.60% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $84.22 million, with a low of $80.1 million and a high of $86.76 million. The median projection represents growth squeezing down to 5.90% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $340.44 million, or 11.40% up from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the FOLD stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 50% Buy. Long term indicators on average place the stock in the category of 100% Buy.
Based on estimates by 13 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 5 have rated the Amicus Therapeutics Inc. (FOLD) stock as a Hold, while 8 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 8.08% off its SMA20 and 8.40% from its 50-day simple moving average. The RSI (14) is pointing at 59.49 while the volatility over the past week is 6.70% and jumps to 5.92% over the past one month. The beta value is 0.86, while the average true range (ATR) is currently pointing at 0.62. The average price target for the stock over the next 12 months is $14.82, with the estimates having a low of $10.00 and a high of $20.00. These price ends are 13.42% and -73.16% off the current price level respectively, although investors could be excited at the prospect of a -29.87% if the FOLD share price touches on the median price of $15.00.
Let’s briefly compare Amicus Therapeutics Inc. (FOLD) stock to its peers. We find that current price change of 6.45% and 2.76% over the past 12 months for FOLD competes that of Biogen Inc. (BIIB), which has seen its stock price rise 1.69% in the last trading session and was 21.61% over the last one year. Another of its peers Novo Nordisk A/S (NVO) has gained 1.74% previous session, and was 3.73% up over the past year, while BioMarin Pharmaceutical Inc. (BMRN) was also up 3.02% in the last session, while its price remained in the green at 0.97% over the same period. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at 1.36% and 1.18%, respectively, at close of the trading.
Coming back to Amicus Therapeutics Inc. (NASDAQ:FOLD), we note that the average 3-month trading volume was 2.64 million. Current shares outstanding are 289.22 million.
The insiders hold 1.00% of the company’s shares. Investors should be excited about this stock as its upside potential is great.